Exelixis Inc

NASDAQ:EXEL   3:59:51 PM EDT
21.63
0.00 (0.00%)
Products, Regulatory

Exelixis In Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead Of Planned Investigational New Drug Application

Published: 12/02/2020 13:20 GMT
Exelixis Inc (EXEL) - Exelixis In-licenses Iconic Therapeutics' Tissue Factor-targeting Antibody-drug Conjugate Ahead of Planned Investigational New Drug Application.
Exelixis Inc - Phase 1 Clinical Trial Planned for Early 2021, Pending FDA's Acceptance of Exelixis' Planned Ind Filing.
Exelixis Inc - Made an Option Exercise Payment of $20 Million to Iconic Therapeutics.